Risk Factors for Invasive Pneumococcal Disease in Children in the Era of Conjugate Vaccine Use

OBJECTIVE: We conducted a case-control study to evaluate risk factors for invasive pneumococcal disease (IPD) among children who were aged 3 to 59 months in the era of pneumococcal conjugate vaccine (PCV7). METHODS: IPD cases were identified through routine surveillance during 2001–2004. We matched a median of 3 control subjects to each case patient by age and zip code. We calculated odds ratios for potential risk factors for vaccine-type and non–vaccine-type IPD by using multivariable conditional logistic regression. RESULTS: We enrolled 782 case patients (45% vaccine-type IPD) and 2512 matched control subjects. Among children who received any PCV7, children were at increased risk for vaccine-type IPD when they had underlying illnesses, were male, or had no health care coverage. Vaccination with PCV7 did not influence the risk for non–vaccine-type IPD. Presence of underlying illnesses increased the risk for non–vaccine-type IPD, particularly among children who were not exposed to household smoking. Non–vaccine-type case patients were more likely than control subjects to attend group child care, be male, live in low-income households, or have asthma; case patients were less likely than control subjects to live in households with other children. CONCLUSIONS: Vaccination with PCV7 has reduced the risk for vaccine-type IPD that is associated with race and group child care attendance. Because these factors are still associated with non–vaccine-type IPD risk, additional reductions in disparities should be expected with new, higher valency conjugate vaccines.

[1]  W. Schaffner,et al.  Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. , 2008, The Journal of infectious diseases.

[2]  M. Farley,et al.  Effectiveness of the 7-Valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease in the First Decade of Life , 2008, Pediatrics.

[3]  Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24-59 months who are not completely vaccinated. , 2008, MMWR. Morbidity and mortality weekly report.

[4]  B. Schwartz,et al.  Uptake of pneumococcal conjugate vaccine among children in the 1998-2002 United States birth cohorts. , 2008, American journal of preventive medicine.

[5]  K. Wolter,et al.  Effect of Vaccine Shortages on Timeliness of Pneumococcal Conjugate Vaccination: Results From the 2001–2005 National Immunization Survey , 2007, Pediatrics.

[6]  W. Schaffner,et al.  Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Stephanie A. Jones,et al.  Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. , 2007, Vaccine.

[8]  W. Schaffner,et al.  Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study , 2006, The Lancet.

[9]  L. Barker,et al.  Impact of state vaccine financing policy on uptake of heptavalent pneumococcal conjugate vaccine. , 2006, American journal of public health.

[10]  E. Lewis,et al.  Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults. , 2006, Vaccine.

[11]  W. Schaffner,et al.  Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. , 2006, JAMA.

[12]  J. Stockman.  Impact of Childhood Vaccination on Racial Disparities in Invasive Streptococcus pneumoniae Infections , 2006 .

[13]  Challenges in global immunization and the Global Immunization Vision and Strategy 2006-2015. , 2006, Releve epidemiologique hebdomadaire.

[14]  S. Madhi,et al.  Quantitative and Qualitative Antibody Response to Pneumococcal Conjugate Vaccine Among African Human Immunodeficiency Virus-Infected and Uninfected Children , 2005, The Pediatric infectious disease journal.

[15]  W. Schaffner,et al.  Elimination of Racial Differences in Invasive Pneumococcal Disease in Young Children After Introduction of the Conjugate Pneumococcal Vaccine , 2004, The Pediatric infectious disease journal.

[16]  S. Schrag,et al.  Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. , 2004, JAMA.

[17]  S. Kaplan,et al.  Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. , 2004, Pediatrics.

[18]  Steven Black,et al.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The Journal of pediatrics.

[19]  S. Madhi,et al.  A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. , 2003, The New England journal of medicine.

[20]  A. Schuchat,et al.  Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. , 2001, JAMA.

[21]  L. Harrison,et al.  Active bacterial core surveillance of the emerging infections program network. , 2001, Emerging infectious diseases.

[22]  K. O'Brien,et al.  Safety and Immunogenicity of Heptavalent Pneumococcal Vaccine Conjugated to CRM197 Among Infants With Sickle Cell Disease , 2000, Pediatrics.

[23]  Cynthia G. Whitney,et al.  Preventing pneumococcal disease among infants and young children : recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2000 .

[24]  J. Butler,et al.  Serotype distribution and antimicrobial resistance patterns of invasive isolates of Streptococcus pneumoniae: Alaska, 1991-1998. , 2000, The Journal of infectious diseases.

[25]  D. Dennis,et al.  Surveillance for Lyme disease--United States, 1992-1998. , 2000, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[26]  M. Kolczak,et al.  Cigarette smoking and invasive pneumococcal disease , 2000 .

[27]  S. Pelton.  Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. , 2000, Pediatrics.

[28]  Russell Larsen,et al.  Neural tube defect surveillance and folic acid intervention--Texas-Mexico border, 1993-1998. , 2000, MMWR. Morbidity and mortality weekly report.

[29]  J. Koplan.  Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2000, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[30]  L. Harrison,et al.  Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. , 1999, Pediatrics.

[31]  L. Vernacchio,et al.  Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. , 1998, The Journal of pediatrics.

[32]  T. Murphy,et al.  Invasive pneumococcal disease in Dallas County, Texas: results from population-based surveillance in 1995. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  B. Gessner,et al.  Risk factors for invasive disease caused by Streptococcus pneumoniae among Alaska native children younger than two years of age. , 1995, The Pediatric infectious disease journal.

[34]  M. Santosham,et al.  High incidence rates of invasive pneumococcal disease in the White Mountain Apache population. , 1992, Archives of internal medicine.